CCR4 and adult T-cell leukemia/lymphoma: Several novel agents have been used for ATLL in clinical settings, including anti-CCR4 antibody (mogamulizumab), HDAC inhibitor (chidamide), and EZH1/2 inhibitor (valemetostat).